Geriatric Medicines Market Report 2025

This Geriatric Medicines market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

The geriatric medicines market size has grown rapidly in recent years. It will grow from $1.22 trillion in 2024 to $1.43 trillion in 2025 at a compound annual growth rate (CAGR) of 16.5%. The growth observed during the historic period can be attributed to factors such as the increasing prevalence of stroke, the rising incidence of chronic diseases, a growing prevalence of cardiovascular diseases, increased government support, and a heightened emphasis on personalized medicine.

The geriatric medicines market size is expected to see rapid growth in the next few years. It will grow to $2.6 trillion in 2029 at a compound annual growth rate (CAGR) of 16.2%. The growth projected for the forecast period can be attributed to factors such as the increasing prevalence of age-related health conditions, a growing geriatric population, rising healthcare expenditures, the expansion of geriatric medicine, and a higher incidence of hypertension. Key trends expected during this period include the use of digital pills and wearable health devices, the development of tools and strategies to manage multiple medications safely, advancements in stem cell and gene therapy, the expanded use of telehealth platforms, and innovations in early diagnosis and prevention of age-related diseases.

The growth of the geriatric medicines market is expected to be driven by the rising prevalence of age-related health conditions. These conditions become more common or severe with aging, largely due to the natural aging process. Factors such as increased life expectancy, advancements in healthcare, and a growing elderly population contribute to the higher occurrence of these health issues. Geriatric medicines are crucial in managing these age-related conditions, offering specialized treatments that enhance the quality of life and healthcare outcomes for older individuals. For example, a report by the Office for Health Improvement and Disparities (OHID) in March 2023 revealed that 17.6% of individuals aged 16 and older in the UK reported having a long-term musculoskeletal (MSK) condition, such as arthritis or chronic joint problems, in 2022. This represents an increase from 17% in 2021. Consequently, the rising prevalence of age-related health conditions is propelling the growth of the geriatric medicines market.

Leading companies in the geriatric medicines market are focusing on developing innovative diabetes therapies to meet the growing demand for effective treatments in the aging population. Diabetes therapy involves cutting-edge treatments that improve management or offer potential cures, aiming to surpass traditional methods in terms of safety, efficacy, and patient outcomes. For example, in August 2023, Akums Drugs & Pharmaceuticals Ltd., a pharmaceutical company based in India, introduced a novel combination therapy of Vildagliptin SR and Metformin SR. This new formulation is designed specifically to manage Type 2 diabetes in elderly patients, offering improved glycemic control while addressing key concerns such as hypoglycemia and weight gain, which are especially important for this group. The combination works by enhancing insulin secretion and lowering blood sugar levels, providing both safety and effectiveness. The product has been approved by the Drug Controller General of India (DCGI).

In October 2023, Zydus Pharmaceuticals UK Limited, a pharmaceutical company based in the UK, acquired LiqMeds Group for an undisclosed sum. This acquisition is intended to strengthen Zydus Life Sciences' position in the expanding oral liquid products market, addressing the specific needs of geriatric and pediatric patients. LiqMeds Group, also based in the UK, specializes in oral liquid formulations, which are particularly advantageous for elderly patients.

Major players in the geriatric medicines market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, Novartis AG, F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Eli Lilly and Company, Viatris Inc., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim GmbH, Regeneron Pharmaceuticals Inc., Macleods Pharmaceuticals Ltd., Apotex Inc., Intas Pharmaceuticals Limited, Dr. Reddy's Laboratories, Lupin Limited, Biocon Limited, Torrent Pharmaceuticals Ltd., and Endo Pharmaceuticals Inc.

North America was the largest region in the geriatric medicines market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in geriatric medicines report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the geriatric medicines market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Geriatric medicines are medications specifically prescribed for individuals aged 65 and older, addressing their unique health needs. These medications are formulated to support cognitive function, mobility, and immune health while taking into account the physiological changes that impact drug metabolism in older adults. They are commonly used to manage chronic conditions and age-related symptoms, ultimately enhancing the overall quality of life for the elderly.

The main therapeutics used in geriatric medicines include analgesics, antihypertensives, statins, proton pump inhibitors, anticoagulants, antipsychotics, and others. Analgesics are essential in geriatric care to manage chronic pain, improve mobility, and enhance the quality of life. These medications are applied in various conditions such as cardiovascular disease, arthritis, neurological disorders, cancer, osteoporosis, and respiratory issues, among others. They are administered through different routes, including oral, parenteral, and others, and are distributed through various channels, such as hospital pharmacies, retail pharmacies, and online pharmacies.

The geriatric medicines market research report is one of a series of new reports that provides geriatric medicines market statistics, including the geriatric medicines industry global market size, regional shares, competitors with the geriatric medicines market share, detailed geriatric medicines market segments, market trends, and opportunities, and any further data you may need to thrive in the geriatric medicines industry. These geriatric medicines market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The geriatric medicines market consists of sales of antidepressants, diuretics, antidiabetics, and anticonvulsants. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.